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Microglia are the primary immunocompetent cells in brain tissue and microglia-mediated inflammation is associated
with the pathogenesis of various neuronal disorders. Recently, many studies have shown that mesenchymal stem
cells (MSCs) display a remarkable ability to modulate inflammatory and immune responses through the release of a
variety of bioactive molecules, thereby protecting the central nervous system. Previously, we reported that MSCs
have the ability to modulate inflammatory responses in a traumatic brain injury model and that the potential
mechanisms may be partially attributed to upregulated TNF-α stimulated gene/protein 6 (TSG-6) expression.
However, whether TSG-6 exerts an anti-inflammatory effect by affecting microglia is not fully understood. In this
study, we investigated the anti-inflammatory effects of MSCs and TSG-6 in an in vitro lipopolysaccharide
(LPS)-induced BV2 microglial activation model. We found that MSCs and TSG-6 significantly inhibited the
expression of pro-inflammatory mediators in activated microglia. However, MSC effects on microglia were attenuated
when TSG-6 expression was silenced. In addition, we found that the activation of nuclear factor (NF)-κB and
mitogen-activated protein kinase (MAPK) pathways in LPS-stimulated BV2 microglial cells was significantly inhibited
by TSG-6. Furthermore, we found that the presence of CD44 in BV2 microglial cells was essential for MSC- and
TSG-6-mediated inhibition of pro-inflammatory gene expression and of NF-κB and MAPK activation in BV2 microglial
cells. The results of this study suggest that MSCs can modulate microglia activation through TSG-6 and that TSG-6
attenuates the inflammatory cascade in activated microglia. Our study indicates that novel mechanisms are responsible
for the immunomodulatory effect of MSCs on microglia and that MSCs, as well as TSG-6, might be promising therapeutic
agents for the treatment of neurotraumatic injuries or neuroinflammatory diseases associated with microglial activation.Introduction
Microglia, which are derived from primitive myeloid
progenitor cells, are the resident immune cells of the
central nervous system (CNS) [1]. As CNS-specific mac-
rophages, they play a critical role in immune surveillance
and homeostatic maintenance of the CNS [2]. They are
highly responsive to stress and injury and become imme-
diately and focally activated in response to brain injuries,
systemic infections, and chronic diseases [3,4]. Further-
more, microglia are involved in initiating inflammatory* Correspondence: jiangxiao_dan@163.com
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unless otherwise stated.responses in the brain through secreting a variety of in-
flammatory mediators, including tumor necrosis factor
(TNF)-α, interleukin (IL)-1β, IL-6, and nitric oxide (NO)
[5,6]. Many recent studies have attributed neuronal dam-
age to the inflammatory responses of the microglia rather
than to a direct neurotoxic insult [7,8]. Reactive microglia
are a common feature of numerous types of brain path-
ology [9]. Therefore, modulating microglia function and
activity appears to be an attractive approach to treating
CNS injuries.
Mesenchymal stem cells (MSCs) are a population of
heterogeneous multipotent cells that reside primarily in
bone marrow but can be found in various postnatal or-
gans and tissues, such as adipose tissue [10], umbilical
cord blood [11], and amniotic fluid [12]. These cells areThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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differentiate into several cellular phenotypes in vitro and
in vivo. Due to their self-renewal and potential multiline-
age properties, MSCs appear to be an ideal cellular source
for the repair of CNS injuries. Previous studies have tested
the therapeutic potential of MSCs in treating CNS injuries,
including traumatic brain injury (TBI), stroke, and spinal
cord injury in animal models. The results of these studies
suggested that transplanted MSCs have beneficial effects
on CNS injuries. For instance, MSCs may promote func-
tional neurological recovery, decrease apoptosis levels, fos-
ter endogenous neurogenesis, improve angiogenesis, and
reduce lesion size [13].
The initial assumption in exploring the mechanisms
by which MSCs ameliorate CNS injury was that they mi-
grated to the injured tissues and transdifferentiated to
replace damaged neural cells [13,14]. However, recent stud-
ies showed that transplanted MSCs exert their therapeutic
effect without evidence of engraftment [15,16], which indi-
cated that their regenerative and differentiating abilities
may not play a role in enhancing tissue repair or limiting
tissue destruction. Instead, MSCs that are stimulated via an
inflammatory signal secrete a variety of bioactive molecules,
such as trophic factors and anti-inflammatory molecules,
to modulate the host microenvironment [17], which may
be the main mechanism responsible for their therapeutic
effects [18].
We recently showed that MSCs can modulate
inflammation-associated cytokine release and immune
cell activation during TBI-induced cerebral inflammatory
responses. We also showed that the beneficial effects of
MSCs may be partially explained by the effect of TSG-6
on the nuclear factor (NF)-κB pathway [19]. However,
whether TSG-6 exerts an anti-inflammatory effect by dir-
ectly affecting the resident inflammatory cells of the CNS
(mainly microglial cells) remains unclear.
To understand the mechanism of the effects of MSCs
on neuroinflammation induced by microglia, we used the
in vitro lipopolysaccharide (LPS)-induced BV2 microglial
activation model. Changes in the expression of pro-
inflammatory mediators and in members of intracellular
signaling pathways by microglia in response to the LPS
stimulus were evaluated. The results indicated that TSG-6
expression by MSCs plays a vital role in suppressing
LPS-induced overactivation of BV2-microglial cells.
Moreover, CD44 expression by microglial cells is essen-




Six-to-eight-week-old female BALB/c mice were purchased
from the Laboratory Animal Center of the Southern Med-
ical University (Guangzhou, China). All animal experimentswere conducted in accordance with the National Insti-
tutes of Health Guide for the Care and Use of Labora-
tory Animals (National Institutes of Health publication
number 80-23, 1996 revision). All experimental proce-
dures were approved by the Southern Medical University
Ethics Committee.
Mesenchymal stem cells isolation and culture
MSCs were prepared from mouse bone marrow (BM)
cells, as previously described [20], with minor modifica-
tions. MSCs were isolated from the BM of the tibias and
femurs of male BALB/c mice. The cells were plated in
25-cm2 culture flasks containing Dulbecco’s modified
Eagle medium (DMEM; Gibco, Grand Island, New York,
United States) supplemented with 10% heat-inactivated
fetal bovine serum (FBS; Gibco), 10 nM GlutaMAX-I
supplement (Invitrogen, Raritan, New Jersey, United
States), 100 U/ml penicillin, 100 μg/ml streptomycin
(Hyclone, Logan, Utah, United States), and 10 μg/ml
gentamycin (Hyclone) and were grown at 37°C in a hu-
midified 5% CO2 atmosphere. After a 48-hour incuba-
tion, the non-adherent cells were removed and fresh
culture medium was added to the flasks. One-half of the
medium was replaced twice a week. When the cells
reached 80 to 90% confluence, adherent cells were tryp-
sinized, harvested, and expanded. MSC were assessed
using flow cytometry to detect cells that expressed the
typical markers CD106, CD44, and Sca-1, and that were
negative for CD11b, CD45, and MHC-II (Additional file 1:
Figure S1). The MSCs used in the experiments were from
passages 6 to 8.
Activation of mesenchymal stem cells using TNF-α
Before being utilized in co-cultures, MSCs were acti-
vated using TNF-α, as described previously [21]. In brief,
MSCs were plated at 2 × 105 cells per well in 6-well plates
containing 2 mL of DMEM with 10% heat-inactivated FBS
and were incubated for 1 day. The medium was then
changed to DMEM containing 2% heat-inactivated FBS
and 10 ng/mL TNF-α (R&D Systems, Minneapolis,
Minnesota, United States). After incubation for 18 hours,
the cells were trypsinized using 0.25% trypsin (Gibco) for
3 minutes at 37°C. To confirm the increased expression of
TSG-6, RNA was extracted from cell aliquots (TRIzol™,
Invitrogen) and assayed for TSG-6 expression using real-
time RT-PCR (Additional file 2: Figure S2).
Transfection of mesenchymal stem cells with TSG-6 siRNA
A total of 2 × 105 MSCs were plated in 6-well dishes and
cultured for 24 hours. The cells were then transfected
with TSG-6 siRNA or control siRNA (sc-39820, sc-37007;
Santa Cruz Biotechnology Inc, Paso Robles, California,
United States) using Lipofectamine™ 2000 according to
the manufacturer’s instructions (Invitrogen). To confirm
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tracted from aliquots of the cells after 48 hours and ana-
lyzed for TSG-6 expression using real-time RT-PCR
(Additional file 3: Figure S3).
BV2 cell culture
The BV2 murine microglial cell line was obtained from
Xiehe Medical University (Beijing, China). The cells were
cultured in a humidified incubator at 37°C with 5% CO2
in DMEM supplemented with 10% heat-inactivated FBS,
100 μg/ml streptomycin, 100 U/ml penicillin (Hyclone),
and 2 mmol/l glutamine (Invitrogen) at 37°C in a humidi-
fied atmosphere containing 5% CO2. A 6-well transwell
system (0.3-mm pore size membrane; Corning, Cam-
bridge, Massachusetts, United States) was used to assess
the effect of MSCs on BV2 cells that were stimulated
using LPS. A total of 5 × 105 BV2 cells were placed in the
lower chamber and stimulated with or without 100 ng/mL
of LPS in the presence of one of the following treatments
in the upper chamber (recombinant mouse TSG-6 protein
(rmTSG-6) was added directly to the microglial cultures
during the LPS treatment): 1) control medium, 2) 1.0 ×
105 TNF-α-activated MSCs, 3) 1.0 × 105 activated MSCs
transfected withTSG-6 siRNA, 4) 1.0 × 105 activated MSCs
transfected with control siRNA, 5) rmTSG-6 at 1 ng/ml, 6)
rmTSG-6 at 10 ng/ml, or 7) rmTSG-6 at 100 ng/ml.
RNA isolation and quantification real-time polymerase
chain reaction (qRT-PCR)
After 6 hours of treatment, the expression levels of
TNF-α, IL-1β, IL-6, and induced nitric oxide synthase
(iNOS) mRNA in BV2 cells were evaluated using real-
time PCR. In brief, total RNA was isolated from BV2
cells using TRIzol™ reagent (Invitrogen) according to the
manufacturers’ instructions. Total RNA from each sam-
ple was reverse transcribed using oligo dT and Super-
Script III RT (Invitrogen). qRT-PCR was conducted
using an ABI 7500HT rapid real-time PCR system (Ap-
plied Biosystems, Foster City, California, United States).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
employed as the endogenous control. The sequence-
specific primers used for the above genes are listed in
Additional file 4: Table S1. The 2−ΔΔCt method was
employed to calculate relative expression levels.
Western blotting analysis
Western blotting was performed to assess whether TSG-
6 affected the downstream TLR4 signaling pathways of
the BV2 cells. LPS-activated BV2 cells were cultured in
the presence of 10 ng/ml rmTSG-6 (R&D Systems) for
15, 30, or 60 minutes, and total proteins were extracted
using RIPA lysis buffer (sc-24948; Santa Cruz Biotech-
nology, California, United States). Protein concentrations
were estimated using a bicinchoninic acid (BCA) proteinassay kit (Thermo Scientific, Pierce, Rockford, Illinois,
United States). The proteins were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride membranes
(Millipore, Billerica, Massachusetts, United States). The
membranes were blocked using 5% non-fat dry milk in
Tris-Buffered Saline and Tween 20 (TBST) and then in-
cubated with primary antibodies directed against JNK,
p38, Erk, phospho-JNK, phospho-p38 or phospho-Erk
(Cell Signaling Technology, Danvers, Massachusetts,
United States) at a 1:1000 dilution at 4°C overnight. The
secondary antibodies were applied for 1 hour at room
temperature. The immunoblots were visualized using en-
hanced chemiluminescence (ECL; Thermo Scientific). The
cellular expression levels were normalized to GAPDH
(Cell Signaling Technology).
Immunofluorescence and laser-scanning confocal
microscopy
Immunofluorescence staining and laser-scanning confocal
microscopy were performed as previously described. BV2
cells were grown on poly-L-lysine- (Sigma, St Louis, MO,
USA) coated glass slides for 12 hours. BV2 cells were
stimulated using LPS in the presence of 10 ng/ml rmTSG-
6 for 1 hour. After treatment, the cells were washed
using PBS and fixed using 4% paraformaldehyde at
room temperature. The cells were exposed to a primary
antibody directed against NF-κB p65 (rabbit monoclonal
NF-κB p65 antibody, 1:200) at 4°C overnight. Following
primary antibody incubation, the slides were incubated
with the secondary antibody (Alexa Fluor 594 goat anti-
rabbit IgG (1:200)) for 1 hour at room temperature. After
three washes using PBS, the slides were incubated with 5
μg/ml FITC-Phalloidin (Sigma) for 20 minutes at room
temperature. The slides were mounted using ProLong®
Gold Antifade Reagent containing 4', 6-diamidino-2-phe-
nylindole (DAPI, Invitrogen). Images were obtained using
an Olympus FV1000 confocal microscope (Olympus,
Tokyo, Japan) and analyzed using FV10-ASW 3.0 Viewer
software (Olympus). The percentage of cells with NF-κB
p65 staining localized to the nucleus was determined by
examining at least 100 cells per slide.
Electrophoretic mobility shift assay (EMSA)
To examine the binding of NF-κB to DNA, nuclear ex-
tracts were prepared using NE-PER Nuclear and Cytoplas-
mic Extraction Reagents (Thermo Scientific). Synthetic
complementary NF-κB-binding oligonucleotides (5′-AGT
TGAGGG GAC TTT CCC AGG C-3′) (Santa Cruz Bio-
technology) were biotinylated using a biotin 3′-DNA label-
ing kit (Thermo Scientific) according to the manufacturer’s
instructions. The binding reactions were conducted for 20
minutes at room temperature in the presence of 50 ng/ml
poly(dI-dC), 0.05% Nonidet P-40, 5 mM MgCl2, 10 mM
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cerol in 1 × binding buffer (LightShift chemiluminescent
EMSA kit, Thermo Scientific) with 20 fmol biotin-end-
labeled target DNA and 10 μg of nuclear extract. The sam-
ples were loaded onto 6.5% non-denaturing polyacrylamide
gels pre-electrophoresed in 0.5 × Tris/Boric Acid/EDTA
(TBE) buffer at 100 V for 60 minutes and were electropho-
resed in 0.5 × TBE buffer at 100 V for 45 minutes. Then,
the samples were transferred to a positively charged nylon
membrane (Millipore) in 0.5 × TBE on ice at 390 mA for
30 minutes. The transferred DNAs were cross-linked to
the membrane at 120 mJ/cm2 and detected using horserad-
ish peroxidase-conjugated streptavidin (Thermo Scientific)
according to the manufacturer’s instructions.Transient transfection of NF-κB reporter construct and
luciferase assay
The level of transcriptional activity of the NF-κB gene
was measured using an NF-κB luciferase reporter gene
assay (Promega, Madison, Wisconsin, United States).
Briefly, BV2 cells were seeded at a density of 1 × 105 in
24-well plates and co-transfected with 0.2 μg of the
pNF-κB-luciferase reporter plasmid (Bayotime, Shanghai,
China) and 0.02 μg of the pRL-TK control plasmid (Pro-
mega) using Lipofectamine™ LTX (Invitrogen) according
to the manufacturer’s protocol. After 24 hours, the
culture medium was replaced with DMEM, and LPS
stimulation was conducted in the presence of MSCs or
TSG-6. Luciferase activity levels were determined using
the Dual-Luciferase reporter Assay System (Promega)
and normalized to that of Renilla reniformis. The altered
luciferase activity was described as the relative ratio to
the control activity.Transfection of BV2 cells with CD44 siRNA
To knockdown CD44 expression, BV2 cells were trans-
fected with CD44 siRNA or control siRNA (sc-35534,
sc-37007; Santa Cruz Biotechnology) using Lipofecta-
mine™ 2000 (Invitrogen) according to the manufac-
turer’s instructions. After 48 hours, CD44 knockdown
was assessed using western blotting and immunofluor-
escence assays.Statistical analyses
All experiments were performed at least three times,
and the data are expressed as the mean value ± SD. Stat-
istical analyses were performed using SPSS 13.0 software
(SPSS, Chicago, Illinois, United States). A one-way ana-
lysis of variance (ANOVA) was used to determine the
significance of differences between the groups. Signifi-
cance was set at a level of P <0.05.Results
Mesenchymal stem cells and TSG-6 suppressed the
lipopolysaccharide-induced pro-inflammatory gene
expression of microglia
We first investigated whether the mRNA expression of
the anti-inflammatory gene TSG-6 was increased in MSCs
that had been stimulated by the inflammatory cytokine
TNF-α. Using qRT-PCR analysis, we found that in re-
sponse to TNF-α stimulation, MSCs expressed TSG-6
mRNA to a level seven-fold higher than the control level
(Additional file 2: Figure S2). Next, we investigated the ef-
fect of MSCs and TSG-6 on the expression of inflamma-
tory factors by LPS-activated microglia. To this end, BV2
microglial cells were co-cultured with MSCs and rmTSG-
6 at different concentrations for 6 hours. As shown in
Figure 1, we observed a significant decrease in the levels
of TNF-α, IL-1β, IL-6, and iNOS mRNA expression when
LPS-stimulated BV2 cells were cultured in the presence of
MSCs. However, the MSCs had reduced effects when the
expression of the TSG-6 gene was knocked down using
TSG-6 siRNA compared with non-transfected MSCs or
control siRNA transfected MSCs. To confirm the key role
of TSG-6 in modulating the function and activity of the
LPS-activated microglia, we added rmTSG-6 directly to
the microglial cultures during LPS treatment. TSG-6 sup-
plementation largely reproduced the effects of the MSCs
in a dose-dependent manner. The results shown in
Figure 1 demonstrate that in the presence of 10 ng/ml and
100 ng/ml of TSG-6, the levels of TNF-α, IL-1β, IL-6, and
iNOS mRNA expression by the BV2 microglia were sig-
nificantly reduced, similar to those produced by acti-
vated MSCs.
TSG-6 interfered with the lipopolysaccharide-induced
activation of NF-κB signaling
The above results indicate that TSG-6 was involved in
reducing the level of LPS-mediated expression of inflam-
matory mediators in BV2 cells. Thus, we investigated
whether TSG-6 played a role in the inflammatory signal-
ing events triggered by LPS stimulation. Because NF-κB is
a major transcription factor mediating pro-inflammatory
gene expression in the LPS-TLR4 signaling pathway [22],
we examined possible alterations in NF-κB signaling in-
duced by TSG-6 in BV2 microglia. First, we analyzed NF-
κB p65 nuclear translocation in BV2 cells using immuno-
fluorescence staining and confocal laser-scanning micros-
copy. After a 1-hour treatment, the cells were fixed for
immunostaining. NF-κB p65 largely remained in the cyto-
plasm of the control group under basal (unstimulated)
conditions. Upon LPS stimulation, nuclear translocation
of NF-κB p65 occurred in BV2 cells, but to a lesser extent
in the TSG-6-treated group (Figure 2A, B).
We next evaluated the DNA-binding activity of NF-κB
using a chemiluminescence-based EMSA assay. Nuclear
Figure 1 MSCs and TSG-6 suppress LPS-induced pro-inflammation gene expression of microglia. BV2 cells were co-cultured with MSCs,
TSG-6-siMSCs, or control-siMSCs activated by TNF-α and different concentration of rmTSG-6 (1 ng/ml, 10 ng/ml, 100 ng/ml) and treated with or
without LPS (100 ng/ml) for 6 hours. (A-D), mRNA levels of TNF-α, IL-1β, IL-6, and iNOS were measured by qRT-PCR analyses and quantified as
fold induction over the levels in unstimulated control cells. All transcriptional levels were normalized to GAPDH mRNA levels and determined by
the 2-ΔΔCt method. Values in the bar graphs are presented as mean ± SD. n = 3; *P <0.05; significantly different from LPS-treated cells. Abbreviations:
TSG-6-siMSCs, MSCs transfected with TSG-6 siRNA; Ctrl(control)-siMSCs, MSCs transfected with control siRNA; LPS, lipopolysaccharide; iNOS, induced
nitric oxide synthase.
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stimulation of control and TSG-6-treated cells, and were
used to compare the binding of a biotin-labeled NF-κB-
specific DNA probe . The increase in DNA-protein com-
plex formation was less prominent as early as 0.5 hours
after LPS stimulation in the TSG-6-treated cells than in
the LPS-treated cells (Figure 2C).
Finally, we evaluated NF-κB transcriptional activity
using luciferase reporter assays. pNF-κB-Luc containing
five tandem repeats of an NF-κB consensus binding site
or pRL-TK as the normalization control were transiently
expressed for 24 hours before LPS stimulation. Measure-
ments of the luminescence intensity showed that TSG-6
inhibited LPS-induced NF-κB activation (Figure 2D).
Taken together, the results suggested that TSG-6 wasactively involved in the regulation of TLR4-mediated
NF-κB signaling.
TSG-6 attenuated the lipopolysaccharide-mediated
phosphorylation of p38, JNK and Erk mitogen-activated
protein kinases
Members of the mitogen-activated protein kinase (MAPK)
family, such as p38, JNK, and Erk, are important down-
stream effector molecules that participate in TLR4 signal-
ing, which can mediate pro-inflammatory gene expression
[23]. Therefore, we examined whether TSG-6 might also
disrupt MAPK signaling. BV2 cells were stimulated with
LPS in the presence of 10 ng/ml rmTSG-6 for 15, 30, or
60 minutes. The level of activation of the MAPKs was
then assessed by measuring the levels of phosphorylated
Figure 2 TSG-6 interferes with LPS-induced activation of NF-κB signaling. BV2 cells were stimulated with LPS in the presence and absence
of TSG-6 (10 ng/ml). Cells were immunostained with a primary antibody against NF-κB p65, followed by an Alexa Fluor 594-conjugated secondary
antibody. Actin filaments (green) and cell nuclei (blue) were visualized with FITC-labeled phalloidin and DAPI separately. Cell images were obtained
using a confocal microscopy. (A) Typical micrographs of immunocytochemistry are shown for cytoplasmic and nuclear distribution on NF-κB p65. Scale
bars, 30 μm. (B) The percentages of cells with NF-κB p65 localized to the nucleus were determined by analysis of at least 100 cells per slide. (C) Nuclear
extracts were prepared and processed for chemiluminescence-based NF-κB EMSA experiments. Cells were stimulated with 100 ng/ml LPS with
or without TSG-6(10 ng/ml) for the indicated periods. Nuclear extracts were incubated with a biotin-labeled NF-κB-specific oligonucleotide and
further probed with streptavidin-HRP. The arrow indicates shifted DNA probe for NF-κB and free probe respectively. (D) BV2 cells were co-transfected
with pNF-κB-luciferase reporter plasmid and pRL-TK control plasmid and then treated with or without LPS (100 ng/ml) in appearance or
absence of rmTSG-6 (10 ng/ml) for 6 hours. NF-κB activities were measured by luciferase assay, normalized to luciferase activities of pRL-TK, and
quantified as fold changes over the control (unstimulated BV2 cells). Values are mean ± SD. n = 3; **P <0.01; *P <0.05; significantly different from
LPS-treated cells. Abbreviations: LPS, lipopolysaccharide; NF-κB, nuclear factor (NF)-κB.
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Figure 3A-D, The levels of phosphorylated p38 and JNK
were slightly increased after 15 minutes of treatment in
the LPS and LPS + TSG-6 groups, whereas the differ-
ences between the levels of LPS-induced phosphoryl-
ation of p38 and JNK in the two groups were less
remarkable. The levels of phosphorylated p38 MAPK
and JNK were significantly increased after 30 to 60
minutes of LPS stimulation compared to those of the
control cells, whereas the LPS-induced phosphorylation
of both kinases was relatively attenuated in TSG-6-
treated BV2 cells at 30 and 60 minutes post-stimulation.Phosphorylated Erk levels increased significantly as
early as 15 minutes after LPS stimulation compared
with that of the control cells. However, the LPS-induced
phosphorylation of Erk was significantly reduced in the
presence of TSG-6 at 15, 30, and 60 minutes post-
stimulation. Taken together, these results suggest that
TSG-6 treatment of microglia downregulated LPS/TLR4-
mediated MAPK activation.
The inhibitory effects of TSG-6 were dependent on CD44
A previous study demonstrated that the inhibitory effects
of TSG-6 on zymosan-induced TLR2/NF-kB signaling
Figure 3 TSG-6 suppresses LPS-mediated phosphorylation of p38, JNK, and Erk. BV2 cells were stimulated with LPS in the presence and
absence of rmTSG-6 (10 ng/ml) for the indicated times. Cell lysates were analyzed for the phosphorylated levels of p38, JNK, Erk, and their total
levels by western blotting with the respective specific antibodies. (A) Representative image of protein levels of P38, JNK, and Erk. (B-D) The
phospho:total ratios of p38 (B), JNK (C), and Erk (D) were determined by measurements of band intensities of each protein kinase and quantified
as fold changes over the control (unstimulated BV2 cells). X axis are shown in time slots of 15, 30, and 60 minutes. Values are mean ± SD. n = 3;
**P <0.01; significantly different from LPS-treated cells. Abbreviations: LPS, lipopolysaccharide.
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macrophages. Furthermore, CD44 suppressed NF-κB acti-
vation after LPS stimulation [21]. TSG-6 also can inhibit
the activation of both T-cells and antigen-presenting cells
(APCs) in a CD44-dependent manner [24]. To obtain
insights into the role of CD44 and the relationship be-
tween CD44 and TSG-6 in modulating the activities of
LPS-activated microglia, we repeated some of the above-
reported experiments using BV2 cells in which CD44
expression was knocked down using CD44 siRNA. The ef-
ficiency of the CD44 knockdown was confirmed using
western blotting and immunofluorescence. The expres-
sion of CD44 was significantly reduced (Figure 4A, B).
As shown in Figure 5A and B, the presence of MSCs or
rmTSG-6 had less effect on reducing the expression of
the pro-inflammatory cytokines TNF-α and IL-1β in CD44-
knockdown BV2 cells compared with non-transfected con-
trol cells or control-siRNA-transfected cells. The magnitude
of the LPS-induced increased DNA-binding activity of NF-κB, as well as the degree of NF-κB transcriptional activ-
ity, was significantly higher in CD44-siRNA-transfected
BV2 cells than in non-transfected control cells or
control-siRNA-transfected cells in the presence of MSCs
or rmTSG-6. (Figure 5C, D) Consistent with these obser-
vations, the western blotting results showed that MSCs
or rmTSG-6 had substantially less impact on reducing
the phosphorylation levels of p38 (Figure 5E, F), JNK
(Figure 5E, G) and Erk (Figure 5E, H) MAPKs upon LPS
stimulation in CD44-knockdown BV2 cells compared
with wild-type non-transfected control cells or control-
siRNA-transfected cells. (Figure 5C, D) These results
suggest that CD44 is required for the MSC- and TSG-6-
mediated anti-inflammatory responses.
Discussion
The aims of this study were to determine whether TSG-6
exerted an anti-inflammatory effect by modulating micro-
glia function and to examine the possible underlying
Figure 4 siRNA-mediated downregulation of CD44 expression in BV2 cells. (A) Representative immunofluorescence images of CD44 (green)
in control BV2 cells, CD44-siRNA-BV2 cells, and control-siRNA-BV2 cells. Nuclei are stained with DAPI (blue). Magnification × 400. (B) Western blot
assay was performed to determine CD44 protein expression in extracts of control BV2 cells, CD44-siRNA-BV2 cells, and control-siRNA-BV2 cells.
GAPDH was used as a loading control. Abbreviations: CD44-siRNA-BV2, BV2 cells transfected with CD44 siRNA; control-siRNA-BV2, BV2 cells
transfected with control siRNA, DAPI, 4', 6-diamidino-2-phenylindole.
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stimulated BV2 microglial model to investigate changes
that occurred in pro-inflammatory mediator expression
and in members of inflammatory signaling pathways in
the presence of MSCs or TSG-6. In this study, we found
that MSCs and TSG-6 mediated the LPS-induced inflam-
matory responses of microglia. Our results clearly showed
that MSCs and TSG-6 reduced the LPS-induced expres-
sion of TNF-α, IL-1β, IL-6, and iNOS. In experiments de-
signed to elucidate the molecular mechanism underlying
the anti-inflammatory function of TSG-6 in microglia, we
found that TSG-6 attenuated the LPS-induced activation
of NF-κB signaling and the phosphorylation of p38, JNK,
and Erk Moreover, the anti-inflammatory effect of TSG-6
depended on CD44 expression on BV2 microglial cells.
Microglia are activated by various stresses and by brain
injury in order to provide supportive signals that lead to
neuronal recovery. However, excessive activation of micro-
glia, characterized by robust production and secretion of a
variety of pro-inflammatory mediators, results in neur-
onal injury which is associated with the pathogenesis of
a number of neurological disorders such as multiple
sclerosis, trauma, Parkinson’s disease, and Alzheimer’s
disease [25,26]. Thus, a therapeutic approach targeting
activated microglia may be a promising treatment for
these conditions.
Recently, many studies have demonstrated that MSCs
possess immunomodulatory properties. MSCs can directly
inhibit the proliferation of T and B lymphocytes [27,28],
inhibit dendritic cell maturation and function [29], and
modulate the cytokine-secretion profile of monocytes and
macrophages [30]. MSCs are also known to inhibit the
basal and formyl-methionyl-leucyl-phenylalanine-stimu-
lated production of reactive oxygen species by neutro-
phils [31]. Due to these immunosuppressive properties,
MSC-based therapy has been successfully applied to
various immune-related diseases, such as graft-versus-host disease (GvHD) [32], systemic lupus erythematosus
(SLE) [33], experimental autoimmune encephalomyelitis
[34], and multiple sclerosis (MS) [35].
Previously, we reported that MSCs have the ability to
modulate inflammatory responses in a TBI model and
that the potential mechanisms responsible for the anti-
inflammatory effects of MSCs may be partially ex-
plained by upregulated TSG-6 expression. TSG-6, also
known as TNAIP6, is a 30 kD glycoprotein that is
expressed at substantially higher levels by many cell
types (including MSCs) in response to stimulation by
several pro-inflammatory mediators compared to nor-
mal physiological conditions [36]. Several studies have
shown that TSG-6 produces anti-inflammatory effects
both in vivo and in vitro [15,16,37]. In the present study,
we found that TSG-6 was expressed at a substantially
higher level in MSCs stimulated by TNF-α. The TNF-α-
activated MSCs were co-cultured with BV2 cells followed
by LPS stimulation. MSCs significantly reduced the level
of pro-inflammatory gene expression in BV2 cells. How-
ever, when we utilized MSCs that were transfected with
siRNA directed against TSG-6 in the co-cultures with
activated microglia, we detected a partial restoration of
the expression level of those genes compared with that
of LPS-stimulated BV2 cells in the presence of non-
transfected MSCs. To identify the functional roles of
TSG-6 in microglial inflammatory responses induced by
LPS, we added recombinant TSG-6 protein directly to
microglial cultures during LPS treatment. The recom-
binant TSG-6 protein also reduced the expression of the
pro-inflammatory genes in a dose-dependent manner.
These data demonstrated that TSG-6 has a key role in
MSC-mediated modulation of LPS-activated microglia.
LPS induces microglial activation through the expression
of TLR4, which triggers the association of myeloid differen-
tiation factor 88 (MyD88)-independent and -dependent
pathways. More importantly, the MyD88-dependent
Figure 5 (See legend on next page.)
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Figure 5 CD44 was essential for the MSC- and TSG-6-mediated anti-inflammatory responses. (A, B) BV2 cells, CD44-siRNA-BV2 cells, and
control-siRNA-BV2 cells were incubated for 6 hours with LPS and with or without activated MSCs or TSG-6. The mRNA levels of TNF-α and IL-1β
were measured by qRT-PCR. All transcriptional levels were normalized to GAPDH mRNA levels and determined by the 2-ΔΔCt method. Values are
mean ± SD. n = 3; **P <0.01; significantly different from control BV2 cells or control-siRNA-BV2 cells. (C) NF-κB DNA-binding activities were measured by
EMSA assay. BV2 cells, CD44-siRNA-BV2 cells, and control-siRNA-BV2 cells were incubated for 1 hour with LPS and with or without activated MSCs or
TSG-6. The data are representative of at least three independent experiments. (D) Luciferase reporter assays for NF-κB transcriptional activity in BV2
cells, CD44-siRNA-BV2 cells, and control-siRNA-BV2 cells (conditions as in Figure 2D) Values are mean ± SD. n = 3; *P <0.05; significantly different from
control BV2 cells or control-siRNA-BV2 cells. (E) Cell extracts were prepared from BV2 cells, CD44-siRNA-BV2 cells, and control-siRNA-BV2 cells incubated
for 30 minutes with LPS and with or without activated MSCs or TSG-6, then subjected to immunoblot analysis using antibodies against the
phospho- or total-forms of the three MAPKs. (F-H) Quantification of western blot data. The phospho:total ratios of p38 (F), JNK (G), and Erk (H)
were determined by measurements of band intensities of each protein kinase and quantified as fold changes over the control (unstimulated
BV2 cells). Values are mean ± SD. n = 3; **P <0.01; significantly different from LPS-treated cells. Abbreviations: CD44-siRNA-BV2, BV2 cells
transfected with CD44 siRNA; control-siRNA-BV2, BV2 cells transfected with control siRNA; LPS, lipopolysaccharide; NF-κB, nuclear factor
(NF)-Κb; EMSA, electrophoretic mobility shift assay.
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transcription factors, including NF-κB and MAPKs,
such as p38, JNK, and Erk [23].
NF-κB is a critical transcription factor that regulates
the expression of various pro-inflammatory genes. NF-
κB normally exists in the cytosol under unstimulated
conditions, bound to the inhibitory IκB protein. LPS
stimulation leads to an increase in the nuclear transloca-
tion of NF-κB and in its DNA-binding activity at specific
promoter regions of a variety of pro-inflammatory genes
such as iNOS, TNF-α, IL-1β, and IL-6, which modulates
their expression [22]. To elucidate the molecular mechan-
ism underlying the anti-inflammatory function of TSG-6
in microglia, we first evaluated its effect on NF-κB activity.
The results demonstrated that LPS-induced nuclear trans-
location, DNA-binding activity, and transcriptional activity
of NF-κB in BV2 cells were substantially suppressed by
TSG-6. In addition to the NF-κB pathway, the MAPK
pathway was found to be associated with the LPS-induced
activation of BV2 microglial cells [38,39]. Some studies
have suggested that MAPKs are crucial for the LPS-
stimulated expression of iNOS, COX-2, and TNF-α
[40]. Our study showed that LPS increased the activa-
tion of p38, JNK, and Erk in BV2 cells. However, pre-
treatment with TSG-6 significantly decreased the level
of activation of these kinases in LPS-stimulated micro-
glia. More importantly, we found that the inhibitory ef-
fects of TSG-6 were dependent on CD44 expression on
microglial cells. Because MSCs or TSG-6 inhibited pro-
inflammatory gene expression, NF-κB and MAPK acti-
vation was significantly restored in CD44-knockdown
BV2 cells after LPS stimulation. These results are con-
sistent with previous observations that the inhibitory ef-
fects of TSG-6 on NF-кB signaling were dependent on
CD44 expression on macrophages and that TSG-6
might regulate the activity of TLR pathways upstream of
MyD88 [21]. TSG-6 is capable of binding to hyaluronan
(HA), moreover, TSG-6 and HA have been reported to
form stable complexes that modulate the interaction ofHA with the cell surface receptor CD44 [41], which is
involved in TLR4 signaling through the formation of a
TLR4-CD44 complex. One study has shown that the en-
gagement of CD44 by HA suppressed TLR4 signaling
[42]. In addition, there is an increasing body of evidence
showing that CD44 is a negative regulator of TLR2- and
TLR4-mediated inflammation [43]. Because crosslinking
HA with TSG-6 can significantly alter the affinity of
CD44 for HA, TSG-6 may stabilize the binding of CD44
to HA [44], which are in close proximity to TLR4, thus
hindering the binding of TLR4 agonists and thereby
blocking TLR4 signaling. However, our study does not
definitively support such a mechanism, and thus this hy-
pothesis is only speculative. Further research must be
performed to determine the specific mechanisms of ac-
tion. Another limitation of our article is the lack of
demonstration of the findings in primary microglia, al-
though BV2 microglial cells are commonly used as an
alternative to primary microglia to study various microglial
responses and interactions [20,45,46]. To fully understand
the anti-inflammatory and immunomodulatory properties
of TSG-6, further experiments should focus on the role of
TSG-6 on primary microglia.
In summary, we have demonstrated that following
stimulation with TNF-α, MSCs modulate microglia ac-
tivity through TSG-6. TSG-6 may interact with CD44 on
microglial cells to inhibit LPS-induced activation of
TLR4 signaling, decreasing NF-κB activity and the activa-
tion of MAPK signaling, thus diminishing the levels of ex-
pression of neuroinflammatory cytokines in BV2 microglia.
These results are consistent with the recent evidence that
MSCs can inhibit inflammation through diffusible mole-
cules and that stimulation with certain inflammatory cyto-
kines is essential for MSC-mediated immunosuppression.
Several soluble factors have been reported to be involved
in MSC-mediated immunoregulation, such as PGE2, IDO
[47], and CX3CL1 [48], which are released by MSCs fol-
lowing stimulation with inflammatory factors. Therefore,
in addition to TSG-6, it is apparent that MSCs can produce
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presented here do not rule out the effects of other anti-
inflammatory factors. However, the data obtained in ex-
periments using TSG-6 siRNA and rmTSG-6 demon-
strates that TSG-6 might play a vital role in inhibiting
LPS-stimulated microglial activation.
Conclusions
The results of this study suggest that MSCs mediate
microglial activation and the production of inflammatory
factors through TSG-6. Our data suggest novel mecha-
nisms for the MSC-mediated immunosuppression of
microglia. These findings can not only serve as the basis
for future studies of the beneficial immunomodulatory
effects of MSCs but may also promote the future clinical
application of MSCs to neurotraumatic and/or neuroin-
flammatory disorders in which microglia may play a
major pathogenic role.
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